What would be the scenario of Gene Therapy Cancer Market in upcoming decade?

In human bodies, if a gene gets mutated, due to any deletion or addition, this can hamper the normal functionality of the cells. The cause of these mutations can be varied like environment changes, lifestyle or genetic changes.

However, if these mutations can be targeted and rectified, it might stop the excess abnormal proliferation of the cancerous cells.

Gene therapy

Cancer gene therapy is one of the promising and technologically advanced treatment options to treat cancer. It is a process of identifying the mutation and then rectifying it by either addition, deletion or inactivation of the gene in question.

Gene therapy is a novel way to express the proteins that are lacking and stop the expression of those in excess. Besides cancer, the area is being explored to treat several inherited or acquired disorders such as neurological disorders, Haemophilia, Cystic fibrosis, Severe combined immunodeficiencies, inherited retinal degeneration, and many others.

DelveInsight’s report “Gene Therapies in Oncology - Innovation to Commercialization: Competitive Landscape, Technological Advancements, Market Opportunities & Future Directions, 2018” provides a comprehensive gene therapy market overview, outlay of future oncology market trends, scope of gene therapy in oncology, on-going clinical trials, cancer gene therapy market size in different geographies, potential licensing-in/out opportunities, possible mergers or disinvestments, and so on.

Approved Cancer Gene Therapies

Two major FDA-approved CAR-T cell therapies are Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta).

	Kymriah	Yescarta
Company	Novartis	Kite/Gilead
FDA Breakthrough designation	Yes	Yes
Approval year	August, 2017	October, 2017
Indications	Acute lymphoblastic leukaemia (ALL) Diffuse large B-cell lymphoma (DLBCL)	DLBCL Non-Hodgkin’s lymphoma
Cost of treatment	USD 475,000 USD for ALL USD 373,000 USD for DLBCL	USD 373,000 USD
Treatment Type	Autologous	Autologous

Cancer gene therapy Market

Global cancer gene therapy market was estimated to be around USD 133 Billion in the year 2017. Upon extensive Cancer gene therapy market analysis, the cancer gene therapy market size is expected to increase in the future according to the DelveInsight’s forecast team.

According to IMS, the cancer gene therapy market value will reach up to USD 180-200 Billion in next five years.

Cancer Gene Therapy Pipeline

The cancer gene therapy pipeline constitutes around 47 products which are under development. In the year 2018, the Cancer gene therapy pipeline products in Phase I and II, accounted for almost 43% of the cancer gene therapy pipeline.

Around 11% of the products are in Phase III, 11% in Phase 1, and around 17% have been given the status of IND (Investigational New Drug). Approximately, 19% of the emerging cancer gene therapies are in pre-clinical and early-discovery stage.

Companies involved in developing Cancer gene therapy

Many pharma players are collaborating with other pharma and biotech companies to develop a standard and efficient gene therapy in oncology. DelveInsight’s report ‘Gene Therapies in Oncology’ lists down the potential merger and acquisition opportunities for pharma companies to grasp the maximum Cancer gene therapy market share. Moreover, the launch of the new gene therapies and a good success rate will increase the cancer gene therapy market size in coming years. 

Key players in gene therapy market such as Advaxis, Advantagene, Inovio Pharmaceuticals, Marsala Biotech and SillaJen are leading the race with their products in crucial stages of development.

Emerging therapies like of MultiVir’s Phase II candidate and of other players, such as Replimmune, Turnstone Biologics, and Vyriad are also going to impact the cancer gene therapy market positively.